atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights [Yahoo! Finance]
Atai Beckley N.V - Common Shares (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: Yahoo! Finance
Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024 Dosing commenced in VLS-01 (oral transmucosal DMT) Phase 1b study, with optimized formulation designed to improve pharmacokinetics and patient experience ahead of anticipated Phase 2 trial in TRD Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights. “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need. Much of our rec
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting Atai Beckley N.V - Common Shares news events
Weekly update
A roundup of the hottest topics
ATAI
News
- Atai Life Sciences (ATAI): Assessing an Expensive-Looking Valuation After a Strong Share Price Run [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswire
- Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property PortfolioGlobeNewswire
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 12/5/25 - Form 8-K
- 12/5/25 - Form 424B7
- 11/26/25 - Form 4
- ATAI's page on the SEC website